Catalent CTS, Inc.

ALXN2050 is a potent, reversible, oral, small molecule inhibitor of factor D (FD), an important component of the complement alternative pathway (AP). The complement system is involved in the pathophysiology of proliferative LN and immunoglobulin A nephropathy (IgAN). The objectives of this study are to evaluate the efficacy and safety of oral ALXN2050 compared to placebo, demonstrate proof of concept for the effectiveness of FD inhibition, and determine an effective dose to address unmet medical needs in patients with LN or IgAN treated with background standard of care.